Merck Attains Acceptance for Investigational Grass Pollen Allergy Immunotherapy Tablet

The company has received FDA investigational approval for biologics intended to treat Timothy grass and ragweed pollen.

Merck, known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational Timothy grass pollen (Phleum pratense) allergy immunotherapy tablet (AIT) has been accepted for review by the U.S. Food and Drug Administration (FDA). In March, the company also submitted a BLA to the FDA for its investigational ragweed pollen (Ambrosia artemisiifolia) AIT. 

No votes yet

Merck Insomnia Treatment Shows Positive Phase III Results

In the study, investigative insomnia medicine Suvorexant improved patients' ability to fall and stay asleep.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo.

No votes yet

Merck, American College of Endocrinology Partner on Blood Sugar Basics Game Plan

The program, featuring promotional support from football personalities, is designed to inform diabetes patients about their treatment options and help manage the disease.

The Blood Sugar Basics Game Plan, developed by the American College of Endocrinology (ACE), with support from Merck (NYSE:MRK) (known as MSD outside the United States and Canada), is kicking off to help the nearly 26 million people in the U.S. who have diabetes find new ways to help manage their disease. The interactive, user-friendly program breaks down diabetes management into four easy-to-understand "goals" to help people with type 2 diabetes take small steps toward better management of their disease.

No votes yet
Syndicate content